CATEGORIES: Lupus Nephritis
First posted November 30, 2021, Updated August 10, 2022; Recruiting
This Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of anifrolumab versus placebo as added to SOC (consisting of MMF and glucocorticoids) in adults with active proliferative Class III or Class IV LN (both with or without concomitant Class V).
To Learn More
Contact: AstraZeneca Clinical Study Information at 1-877-240-9479 or firstname.lastname@example.org
ClinicalTrials.gov identifier (NCT number): NCT05138133